Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
CONCLUSIONS: There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and high risk of bias. We have identified an area of large uncertainty for a group of patients who account for most of those diagnosed as having CKD.PMID:37466151 | DOI:10.1002/14651858.CD007751.pub3
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tess E Cooper Claris Teng David J Tunnicliffe Brydee A Cashmore Giovanni Fm Strippoli Source Type: research
More News: Benazepril | Cardiology | Cardiovascular | Chia | China Health | Chronic Kidney Disease | Clinical Trials | Conferences | Congestive Heart Failure | Cozaar | Databases & Libraries | Diabetes | Diabetes Mellitus | Enalapril | Endocrinology | General Medicine | Heart | Heart Attack | Heart Failure | Heart Transplant | Hypertension | Ischemic Stroke | Japan Health | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Losartan | Proteinuria | Stroke | Study | Transplant Surgery | Transplants | Urology & Nephrology